Fujifilm Diosynth Biotechnologies announced the completion of an expansion project at its cell therapy manufacturing facility in Thousand Oaks, Calif., on Nov. 20, 2024 (1). During a celebration for the launch of the expanded facility, the company also recognized the issuance of a Certificate of GMP Compliance of a Manufacturer for the site, which was granted by the European Medicines Agency (EMA). The suites are capable of automated cell separation and selection, with expansion equipment, in-built decontamination for rapid changeovers, and heating, ventilation, and air conditioning systems that can support either Grade B or C backgrounds. Source: Biopharm International 22/11/2024